Dr. John Cush RheumNow
5 years 11 months ago
QD104 - You Are So Not Disabled
QD Clinic - Lessons from the clinic
Grappling with Disability Letter Requests
Features Dr. Jack Cush
https://t.co/Vg5i9rHyKN
Dr. John Cush RheumNow
5 years 11 months ago
Metaanalysis of 7 cohort studies, 34 029 biologic & 135370 biologic-naive Pts (RA, PsO, IBD) looked at risk of melanoma (vs conventional Rx). Found no statistically significant increase risk for melanoma w/ biologics (eg RA RR 1.2; 95% CI, 0.83-1.74) https://t.co/rnZwzqE8m2
QD Clinic - Dealing with Surgeons
Stopping DMARDs & Biologics for Surgery
QD Clinic - You Are So Not Disabled
Grappling with Disability Letter Requests
Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com
Dr. John Cush RheumNow
5 years 11 months ago
Intnl psoriasis registry reports Less hospitalization in PSO on biologics (16% vs 33%); higher HR 2.8 on non-biologics. 374 Psoriasis pts w/ COVID-19, 71% on biologic, 18% non-biologic & 10% no systemic Rx. 93% fully recovered. 21% hospitalized, 2% died. https://t.co/xLaPrkfDCf
An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).
Dr. John Cush RheumNow
5 years 11 months ago
25 pts w/ refractory Juvenile dermatomyositis (JDM) were treated w/ JAK inhib (tofacitinib, ruxolitinib) - all showed improved rashes, including 66.7% with complete resolution; 40% had decreased muscle strength; 28% discontinued glucocorticoids https://t.co/wln0FrI0Iz
Dr. John Cush RheumNow
5 years 11 months ago
Population study from NY of 168,234 hip replacements and 308,477 knee TKAs showed that total joint arthroplasty was associated with a 34-44% decrease risk of falls (THA HR 0.56; TKA HR 0.66). Risk of falls incr w/ age- 70-79 yrs (HR4.3), 80+ yrs (HR 5.5) https://t.co/KeejsfGEjn
While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.
Dr. John Cush RheumNow
5 years 11 months ago
Barer-Flood Prize
Headshot of
Canadian Instit of Health has awarded Dr. Peter Tugwell Barer-Flood Prize, recognizing and exceptional career with a substantial impact on health care policy research, policy, delivery. He is a founding member of Cochrane . https://t.co/qxqUrdEFYz https://t.co/HOuLw4DxP3
QD Clinic - Biologics and Pregancy
Pregnancyy and What to do about drugs and biologics!
Dr. John Cush RheumNow
5 years 11 months ago
Autoantibodies can be found in COVID-19 ptas (including ANA, RF, -RNP centromere and antibobides against phospholipids (3/52), prothrombin (2/52), and c-ANCA (2/52)) (THIS IS A PREPRINT) https://t.co/kN6hVMiNt3 https://t.co/4yNJJhOxXP
QD Clinic- Undulating Fever
FUO and Brucellosis
